 |
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside
SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.
As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration.
"This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond."
NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.
"The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS.
"This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS.
The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond.
"The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options."
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit www.elpisbiopharmaceuticals.com.
Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
jnugent@tiberend.com
Eric Reiss (media)
ereiss@tiberend.com
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside
SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.
As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration.
"This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond."
NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.
"The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS.
"This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS.
The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond.
"The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options."
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit www.elpisbiopharmaceuticals.com.
Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
jnugent@tiberend.com
Eric Reiss (media)
ereiss@tiberend.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
|
DUBAI, UAE, Jan. 23, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO), a company specializing in AI-driven autonomous systems, today announced a three-year Gold Reseller Agreement with The Ghazi Group ("TGG"), a full-stack AI infrastructure and solutions provider. The agreement grants Robo.ai Gold Reseller status to distribute TGG's edge inference servers for fully autonomous vehicles, advanced CPU and GPU server systems, as well as storage and networking systems across the MENA and selected Southeast Asian markets. The partnership is underpinned by Robo.ai's regional integration capabilities, regulatory familiarity, and existing enterprise deployment footprint in the covered markets, addressing the high growth, high potential AI infrastructure demand.
In 2026, the Asia Pacific (APAC) edge AI market is projected to reach approximately $6.0 billion, growing at a compound annual growth rate (CAGR) of 26.8%. The Middle East & Africa (MEA) edge AI market, while currently smaller at an estimated $3.1 billion for the same period, is experiencing rapid growth driven largely by strategic national investments, particularly in the UAE and Saudi Arabia. The partnership between Robo.ai and TGG is positioned to capture a share of this growth, creating a revenue opportunity exceeding $100 million in MENA and Southeast Asia.
This partnership fundamentally transforms Robo.ai's role from an AI robotic platform to a critical 'compute gateway' for enterprise and sovereign AI deployment. By accessing to essential AI infrastructure, Robo.ai is positioned at the strategic intersection of AI software, robotics, and the underlying compute architecture required for large-scale implementation.
Shafi Khan, President and CEO of The Ghazi Group stated, "We are pleased to announce a strategic partnership with Robo.ai to accelerate breakthrough innovation in fully autonomous mobility and support Robo.ai's initiative to become the first Made-in-UAE fully autonomous vehicle manufacturer, and to become a leader in the smart open machine economy. We are committed to supporting our clients and our partners in this unique and strategic market."
Robo.ai CEO Benjamin Zhai stated: "In an era of rapid technological and geopolitical change, Robo.ai has been forging its own path of evolution. Our strategic focus on the AI machine economy is proving its merit. We also recognize that even the best products and R&D cannot stand without foundational infrastructure and compute power. This partnership with TGG is a milestone in building Robo.ai's strategic moat and solidifying our operational foundation."
The collaboration is designed to generate a recurring revenue stream tied to the complete AI deployment lifecycle. Revenue will be driven not only by hardware but also by associated system integration, software licensing, and long-term technical support and service contracts. This model aligns Robo.ai's success directly with the scaling and maintenance of its clients' AI capabilities.
About The Ghazi Group
The Ghazi Group (TGG) is a U.S.-based advanced technology infrastructure supplier focused on enabling high-performance computing deployments for mission-critical AI initiatives. Headquartered in Miami, Florida and registered in Delaware, TGG serves as a certified reseller and delivery partner for Supermicro, Blaize Technologies, and other leading AI technology providers, offering engineering-led sourcing, integration, and deployment of enterprise-grade GPU/CPU platforms, rack-scale server solutions, and edge inference systems for real-time, data-intensive applications. Through a vetted global partner ecosystem, TGG supports large organizations in South Asia and clients across the EMEA Region delivering compliant, scalable compute infrastructure designed to accelerate sovereign AI programs, industrial innovation, and next-generation intelligent mobility.
About Robo.ai Inc.
Robo.ai Inc. (NASDAQ: AIIO) is a technology company based in the UAE, dedicated to developing a global AI-enabled robotics platform. The company aims to create a decentralized AI network for connecting AI terminals and promoting an intelligent future. Their focus includes integrating AI into smart devices and smart assets.
This press release includes "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Actual outcomes may differ materially from expectations — please refer to the company's SEC filings for details.
DUBAI, UAE, Jan. 23, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO), a company specializing in AI-driven autonomous systems, today announced a three-year Gold Reseller Agreement with The Ghazi Group ("TGG"), a full-stack AI infrastructure and solutions provider. The agreement grants Robo.ai Gold Reseller status to distribute TGG's edge inference servers for fully autonomous vehicles, advanced CPU and GPU server systems, as well as storage and networking systems across the MENA and selected Southeast Asian markets. The partnership is underpinned by Robo.ai's regional integration capabilities, regulatory familiarity, and existing enterprise deployment footprint in the covered markets, addressing the high growth, high potential AI infrastructure demand.
In 2026, the Asia Pacific (APAC) edge AI market is projected to reach approximately $6.0 billion, growing at a compound annual growth rate (CAGR) of 26.8%. The Middle East & Africa (MEA) edge AI market, while currently smaller at an estimated $3.1 billion for the same period, is experiencing rapid growth driven largely by strategic national investments, particularly in the UAE and Saudi Arabia. The partnership between Robo.ai and TGG is positioned to capture a share of this growth, creating a revenue opportunity exceeding $100 million in MENA and Southeast Asia.
This partnership fundamentally transforms Robo.ai's role from an AI robotic platform to a critical 'compute gateway' for enterprise and sovereign AI deployment. By accessing to essential AI infrastructure, Robo.ai is positioned at the strategic intersection of AI software, robotics, and the underlying compute architecture required for large-scale implementation.
Shafi Khan, President and CEO of The Ghazi Group stated, "We are pleased to announce a strategic partnership with Robo.ai to accelerate breakthrough innovation in fully autonomous mobility and support Robo.ai's initiative to become the first Made-in-UAE fully autonomous vehicle manufacturer, and to become a leader in the smart open machine economy. We are committed to supporting our clients and our partners in this unique and strategic market."
Robo.ai CEO Benjamin Zhai stated: "In an era of rapid technological and geopolitical change, Robo.ai has been forging its own path of evolution. Our strategic focus on the AI machine economy is proving its merit. We also recognize that even the best products and R&D cannot stand without foundational infrastructure and compute power. This partnership with TGG is a milestone in building Robo.ai's strategic moat and solidifying our operational foundation."
The collaboration is designed to generate a recurring revenue stream tied to the complete AI deployment lifecycle. Revenue will be driven not only by hardware but also by associated system integration, software licensing, and long-term technical support and service contracts. This model aligns Robo.ai's success directly with the scaling and maintenance of its clients' AI capabilities.
About The Ghazi Group
The Ghazi Group (TGG) is a U.S.-based advanced technology infrastructure supplier focused on enabling high-performance computing deployments for mission-critical AI initiatives. Headquartered in Miami, Florida and registered in Delaware, TGG serves as a certified reseller and delivery partner for Supermicro, Blaize Technologies, and other leading AI technology providers, offering engineering-led sourcing, integration, and deployment of enterprise-grade GPU/CPU platforms, rack-scale server solutions, and edge inference systems for real-time, data-intensive applications. Through a vetted global partner ecosystem, TGG supports large organizations in South Asia and clients across the EMEA Region delivering compliant, scalable compute infrastructure designed to accelerate sovereign AI programs, industrial innovation, and next-generation intelligent mobility.
About Robo.ai Inc.
Robo.ai Inc. (NASDAQ: AIIO) is a technology company based in the UAE, dedicated to developing a global AI-enabled robotics platform. The company aims to create a decentralized AI network for connecting AI terminals and promoting an intelligent future. Their focus includes integrating AI into smart devices and smart assets.
This press release includes "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Actual outcomes may differ materially from expectations — please refer to the company's SEC filings for details.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Robo.ai Partners with The Ghazi Group to Power AI Compute Infrastructure Growth in MENA and Southeast Asia
